Ultragenyx Pharmaceutical Inc. - Form 8-K/A Summary
Business Context and Reporting Period
This filing is an Amendment No. 1 to a Current Report on Form 8-K originally filed on June 27, 2022. The report concerns the Annual Meeting of Stockholders held on June 24, 2022. The amendment specifically updates disclosure regarding the Board of Directors' determination on the frequency of future shareholder advisory votes on executive compensation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report and does not contain financial performance data.
Material Changes
There are no material financial changes reported. The only material update is the Board's formal decision to hold annual "Say-on-Pay" advisory votes for executive compensation, aligning with the shareholder preference expressed at the June 24, 2022 meeting.
Guidance, Outlook, and Management Commentary
- Shareholder Vote Outcome: The "every year" option received the highest number of votes for the frequency of future advisory votes on executive compensation.
- Board Determination: The Board has decided to conduct annual advisory votes on executive compensation until the next required frequency vote, which must occur no later than the 2028 annual meeting.
- Risks and Contingencies: No specific risks or contingencies are detailed in this amendment.
Key Facts for Investor Verification
- Confirm the date of the next required shareholder vote on compensation frequency (no later than the 2028 annual meeting).
- Verify that the "every year" option was indeed the top choice in the Say-on-Frequency Proposal.
- Note that this filing is an amendment solely for updating Item 5.07 disclosure and does not alter other information in the initial report.